Company Profile

ImmuNext Inc
Profile last edited on: 5/27/2020      CAGE: 6BYC6      UEI: SBSALV1MKHA3

Business Identifier: Novel immunotherapies for autoimmune disease and cancer
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1 Medical Center Drive
Lebanon, NH 03756
   (603) 493-5390
Location: Single
Congr. District: 02
County: Grafton

Public Profile

With core competencies in discovery, target biology and pre-clinical drug development, ImmuNext is organized around development of immunomodulatory compounds designed to modulate the immune system to treat cancer and autoimmune diseases. Negative checkpoint regulators are changing the way cancer is treated. ImmuNext's lead product, anti-VISTA, is partnered with Janssen for the treatment of cancer. A second product, VISTA agonists, is partnered with Hoffmann-La Roche for the treatment of autoimmune diseases. Other programs include a CD40 agonist for neoantigen cancer vaccines and a novel immuno-metabolic target, in each case establishing new classes of compounds. ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. The immunoregulatory molecule, CD40L, is critical to the progression of a wide spectrum of autoimmune diseases. Antibodies that block the function of CD40L have proven in pre-clinical models of autoimmunity to be effective agents in treating disease. The development of anti-CD40L for the treatment of autoimmune diseases offers a unique opportunity to silence disease progression and offer long-term remission.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  David DeLucia -- Chief Executive Officer

  Matthew F Mackey

  Randolph Noelle -- Chief Scientific Officer

  Michael Rosenzweig -- Vice President of Research and Development

  Jay L Rothstein -- Vice President of Research and Development